Georgia vs United Arab Emirates: Share of E. coli infections resistant to cephalosporins
Georgia
46.5%
in 2022
United Arab Emirates
52.4%
in 2022
Georgia rank
18th
United Arab Emirates rank
17th
Share of E. coli infections resistant to cephalosporins over time
- Georgia
- United Arab Emirates
How they compare
United Arab Emirates currently reports 52.4% against 46.5% in Georgia, a difference of 5.9%.
That makes United Arab Emirates's figure about 1.1 times Georgia's.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was United Arab Emirates ahead.
Georgia ranks 18th and United Arab Emirates ranks 17th of 46 countries.
Across the 2 decades both report, Georgia averaged higher in 1 and United Arab Emirates in 1.
Head to head by decade
| Decade | Georgia | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 53.1% | 47.5% | 5.6% | Georgia |
| 2020s | 41.8% | 52.7% | 10.9% | United Arab Emirates |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Georgia or United Arab Emirates?
- United Arab Emirates, at 52.4% against 46.5% in Georgia as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Georgia and United Arab Emirates?
- 5.9%, with United Arab Emirates ahead.
- How many years of comparable data are there for Georgia and United Arab Emirates?
- 6 years are reported by both, from 2017 to 2022.
- How do Georgia and United Arab Emirates rank globally for share of e. coli infections resistant to cephalosporins?
- Georgia ranks 18th and United Arab Emirates ranks 17th of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).